4 results on '"Hallemans R"'
Search Results
2. Hypoxic pulmonary vasoconstriction in liver cirrhosis.
- Author
-
Naeije R, Hallemans R, Mols P, and Melot C
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Vascular Resistance, Hypoxia physiopathology, Liver Cirrhosis physiopathology, Pulmonary Circulation, Vasoconstriction
- Abstract
Impairment of hypoxic pulmonary vasoconstriction (HPV) is frequently cited as an explanation for the hypoxemia of liver cirrhosis. We investigated the pulmonary and systemic hemodynamic responses to acute inspiratory hypoxia, 12.5 percent oxygen in nitrogen during 10 minutes, in 24 patients with mildly to moderately decompensated liver cirrhosis and arterial hypoxemia. A mean increase of 50 percent in pulmonary vascular resistance (PVR) was observed, which is comparable to reported responses of normal subjects to a similar degree of hypoxia. Seven of the 24 patients showed an increase in PVR of less than 20 percent. Compared with the other patients, no difference could be found between both groups in baseline blood gas and hemodynamic determinations, physical examination, liver function tests, and laboratory tests that may be disturbed by circulating endotoxin. Five of the 24 patients had a hyperkinetic circulatory state, but only one of them failed to increase PVR in response to hypoxia. Considering the whole group of 24 patients, there was no correlation between PaO2, PVR, and PVR response to hypoxia. Impairment of HPV is probably not the right explanation for most cirrhotic patients with arterial hypoxemia.
- Published
- 1981
- Full Text
- View/download PDF
3. Effects of vasodilators on hypoxic pulmonary vasoconstriction in normal man.
- Author
-
Naeije R, Mélot C, Mols P, and Hallemans R
- Subjects
- Adult, Female, Hemodynamics drug effects, Humans, Male, Nifedipine pharmacology, Nitroglycerin pharmacology, Nitroprusside pharmacology, Oxygen blood, Ventilation-Perfusion Ratio drug effects, Hypoxia physiopathology, Pulmonary Circulation drug effects, Vasoconstriction drug effects, Vasodilator Agents pharmacology
- Abstract
A reduction of arterial PO2 is generally observed when vasodilators are given to patients with cardiac or pulmonary disease. This has been attributed to a release of preexisting hypoxic pulmonary vasoconstriction (HPV). We investigated the effects of hemodynamics and blood gases of IV nitroglycerin, IV nitroprusside and sublingual nifedipine, at dosages currently used in clinical practice, in 23 healthy volunteers at normoxic conditions (fraction of inspired O2, FIO2 0.21) and at acute inspiratory hypoxia (FIO2 0.125 during 10 min). Breathing FIO2 0.125 elicited pulmonary vasoconstriction in all the subjects. At FIO2 0.21, nitroglycerin reduced preload, nifedipine reduced afterload, nitroprusside had balanced effects, but none of the drugs induced pulmonary vasodilation and only nitroglycerin deteriorated arterial oxygenation. At FIO2 0.125, nitroglycerin did not at all affect the pulmonary pressor response, while both nitroprusside and nifedipine decreased it. An inhibition of HPV was obtained with certainty in only one subject who received nitroprusside. In all the subjects in whom HPV was partially inhibited by vasodilator administration, the alveolar-arterial PO2 gradients remained significantly lowered, suggesting that the pulmonary vascular tone adaptation to alveolar hypoxia still was effective in improving ventilation/perfusion relationships. The role of impaired HPV in the reduction of arterial PO2 in patients under vasodilator therapy may have to be reevaluated.
- Published
- 1982
- Full Text
- View/download PDF
4. Improvement in ventilation-perfusion matching by almitrine in COPD.
- Author
-
Mélot C, Naeije R, Rothschild T, Mertens P, Mols P, and Hallemans R
- Subjects
- Administration, Oral, Aged, Almitrine, Carbon Dioxide blood, Hemodynamics drug effects, Humans, Lung physiopathology, Lung Diseases, Obstructive physiopathology, Male, Middle Aged, Oxygen blood, Piperazines pharmacology, Pulmonary Circulation drug effects, Central Nervous System Stimulants therapeutic use, Lung Diseases, Obstructive drug therapy, Piperazines therapeutic use, Ventilation-Perfusion Ratio drug effects
- Abstract
Almitrine, a peripheral chemoreceptor stimulating drug, was given 100 mg orally to six patients with advanced chronic obstructive pulmonary disease (COPD), and its effects on hemodynamics, blood gases, lung mechanics, and the distribution of ventilation/perfusion ratios (VA/Q), determined by the inert gas elimination technique, were investigated. Arterial Po2 increased from 52 +/- 4 to 59 +/- 3 mm Hg, mean +/- SEM, p less than 0.01, arterial Pco2 decreased from 46 +/- 3 to 43 +/- 3 mm Hg, p less than 0.05, and venous admixture from 30 +/- 6 to 19 +/- 3 percent, p less than 0.02. No change occurred in ventilation, variables of lung mechanics, systemic and pulmonary hemodynamics, except an increase in pulmonary vascular resistance (from 364 +/- 103 to 438 +/- 99 dyne.s.cm-5, p less than 0.05). A reduction in VA/Q inequality could be demonstrated with a redistribution of blood flow into the lungs by a diversion of 15 percent of total blood flow from units with low VA/Q (between 0.08 and 0.4) to units with normal VA/Q (between 0.5 and 1.8). These changes might be explained by an enhancement of hypoxic pulmonary vasoconstriction. Pharmacologic peripheral chemoreceptor stimulation, at an infra-ventilatory analeptic dosage, might be of therapeutic interest to patients with respiratory insufficiency due to VA/Q inequality.
- Published
- 1983
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.